Retinal Vein Occlusion Market

研究執行與發布：Coherent Market Insights　·　發布日期 2026-06-30　·　250 頁
由量子訊息有限公司（Quantum Information）在台灣代理銷售與提供授權諮詢。

2026 年市場規模: USD 2.96 Bn
2033 年預估規模: USD 4.71 Bn
年複合成長率 CAGR: 6.9%

以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。

出版商 Coherent Market Insights 產業別 Healthcare & Life Sciences出版日期 2026-06-30頁數 250報告編號 CMI9711

授權報價

Single User Price	$4,500 USD
Enterprise License	$10,000 USD

洽詢購買申請 Sample

完整報告名稱與涵蓋範圍

Retinal Vein Occlusion Market, By Disease Type (Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO)), By Treatment Type (Anti-VEGF Therapy, Corticosteroid Therapy, Laser Therapy, and Others), By End User (Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers (ASCs), and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)

報告摘要

The global retinal vein occlusion market is estimated to be valued at USD 2.96 Bn in 2026 and is expected to reach USD 4.71 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 6.9% from 2026 to 2033. Retinal vein occlusion (RVO) is one of the most prevalent of all ocular retinal vascular diseases, and is one of the predominant causes of visual loss worldwide especially the age-related loss of vision. Retinal vein occlusion is caused by the occlusion of an eye’s retinal veins, resulting in the disruption of circulation and subsequently leads to ischemia of retina, retinal edema, and eventually blindness if not appropriately treated. Retinal vein occlusion can be classified into two primary subtypes, central RVO (CRVO) and branch RVO (BRVO) and is linked with a number of prevalent conditions namely hypertension, diabetes, hyperlipemia, and glaucoma. Rapid global aging population along with rising prevalence of these chronic illnesses are adding to the overall burden of retinal vein occlusion. The retinal vein occlusion treatment pipeline is driven by modalities including anti-VEGF agents, corticosteroids, surgery, and laser therapy. Anti-VEGF therapies continue to be the first choice for treating retinal edema linked with retinal vein occlusion. These ongoing innovations, together with emergence of newer drug development as long-acting biologic drugs and their bioequivalents/biosimilars, development of state-of-the-art retinal imaging techniques have resulted in higher standards for patient treatment and broadened accessibility to the therapy over the anticipated timeframe. Market Dynamics The global retinal vein occlusion market is driven by rising prevalence of diabetes, hypertension and cardio vascular diseases. In addition to a growing geriatric populace, this phenomenon contributed towards increasing risks of the diseases related to retinal vessels. Technology advancements such as in optic coherence tomography (OCT) and fluorescence angiography are enabling better early prognosis of the condition, whilst broad application of anti-VEGF drugs have led to successful treatment results in the retinal vein occlusion linked macular oedema. However, a number of constraints are present in the market, such as high treatment cost, repetitive intra vitreal injection treatments and probable side-effects by corticosteroid therapies. Nevertheless, advancements in long-acting drug delivery systems, the emergence of biosimilars, and the next generation retinal therapeutics will offer new opportunities for growth in the retinal vein occlusion market. Key Features of the Study • This report provides in-depth analysis of the global retinal vein occlusion market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the global retinal vein occlusion market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include Regeneron Pharmaceuticals, F. Hoffmann-La Roche Ltd., Bayer AG, AbbVie Inc., Biogen Inc., Samsung Bioepis, Sandoz Inc., Biocon Biologics, Amgen Inc., and Alimera Sciences • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The global retinal vein occlusion market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global retinal vein occlusion market Market Segmentation • Disease Type Insights (Revenue, USD Bn, 2021 - 2033) o Central Retinal Vein Occlusion (CRVO) o Branch Retinal Vein Occlusion (BRVO) • Treatment Type Insights (Revenue, USD Bn, 2021 - 2033) o Anti-VEGF Therapy o Corticosteroid Therapy o Laser Therapy o Others • End User Insights (Revenue, USD Bn, 2021 - 2033) o Hospitals o Ophthalmology Clinics o Ambulatory Surgical Centers (ASCs) o Others • Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033) o Hospital Pharmacies o Retail Pharmacies o Specialty Pharmacies • Regional Insights (Revenue, USD Bn, 2021 - 2033) o North America  U.S.  Canada o Latin America  Brazil  Argentina  Mexico  Rest of Latin America o Europe  Germany  U.K.  Spain  France  Italy  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC Countries  Israel  Rest of Middle East o Africa  South Africa  North Africa  Central Africa • Key Players Insights o Regeneron Pharmaceuticals o F. Hoffmann-La Roche Ltd. o Bayer AG o AbbVie Inc. o Biogen Inc. o Samsung Bioepis o Sandoz Inc. o Biocon Biologics o Amgen Inc. o Alimera Sciences

目錄 Table of Contents

Table of Contents 1. Research Objectives and Assumptions o Research Objectives o Assumptions o Abbreviations 2. Market Purview o Report Description  Market Definition and Scope o Executive Summary  Global Retinal Vein Occlusion Market, By Disease Type  Global Retinal Vein Occlusion Market, By Treatment Type  Global Retinal Vein Occlusion Market, By End User  Global Retinal Vein Occlusion Market, By Distribution Channel  Global Retinal Vein Occlusion Market, By Region 3. Market Dynamics, Regulations, and Trends Analysis o Market Dynamics o Impact Analysis o Key Highlights o Regulatory Scenario o Disease Type Launches/Approvals o PEST Analysis o PORTER’s Analysis o Market Opportunities o Regulatory Scenario o Industry Trends 4. Global Retinal Vein Occlusion Market, By Disease Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Central Retinal Vein Occlusion (CRVO)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Branch Retinal Vein Occlusion (BRVO)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 5. Global Retinal Vein Occlusion Market, By Treatment Type, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Anti-VEGF Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Corticosteroid Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Laser Therapy  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 6. Global Retinal Vein Occlusion Market, By End User, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospitals  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Ophthalmology Clinics  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Ambulatory Surgical Centers (ASCs)  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Others  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 7. Global Retinal Vein Occlusion Market, By Distribution Channel, 2021-2033, (USD Bn) o Introduction  Market Share Analysis, 2026 and 2033 (%)  Y-o-Y Growth Analysis, 2022 - 2033  Segment Trends o Hospital Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Retail Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) o Specialty Pharmacies  Introduction  Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn) 8. Global Retinal Vein Occlusion Market, By Region, 2021 - 2033, Value (USD Bn) o Introduction  Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)  Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)  Regional Trends o North America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o U.S. o Canada o Latin America  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Brazil o Argentina o Mexico o Rest of Latin America o Europe  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o Germany o U.K. o Spain o France o Italy o Russia o Rest of Europe o Asia Pacific  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o China o India o Japan o Australia o South Korea o ASEAN o Rest of Asia Pacific o Middle East  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn) o GCC Countries o Israel o Rest of Middle East o Africa  Introduction  Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Treatment Type, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)  Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn) o South Africa o North Africa o Central Africa 9. Competitive Landscape o Regeneron Pharmaceuticals  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies o F. Hoffmann-La Roche Ltd.  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies o Bayer AG  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies o AbbVie Inc.  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies o Biogen Inc.  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies o Samsung Bioepis  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies o Sandoz Inc.  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies o Biocon Biologics  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies o Amgen Inc.  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies o Alimera Sciences  Company Highlights  Disease Type Portfolio  Key Developments  Financial Performance  Strategies 10. Analyst Recommendations o Wheel of Fortune o Analyst View o Coherent Opportunity Map 11. References and Research Methodology o References o Research Methodology o About us *Browse 32 market data tables and 28 figures on ‘Retinal Vein Occlusion Market' - Global forecast to 2033

提及公司

Regeneron PharmaceuticalsF. Hoffmann-La Roche Ltd.Bayer AGAbbVie Inc.Biogen Inc.Samsung BioepisSandoz Inc.Biocon BiologicsAmgen Inc.Alimera Sciences

同分類最新報告（醫療與生命科學）

常見問題

這份報告可以先索取樣本嗎？

可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。

報告價格如何計算？

報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。

下單後多久交付？如何付款？

一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。

量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・聯絡我們